XML 16 R6.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Mar. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Cash flows used in operating activities:              
Net loss $ (3,724) $ (2,720) $ (1,728) $ (1,087) $ (9,244) $ (4,654)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation and amortization         266 273  
Amortization of deferred financing costs and debt discount         417 428  
Loss on disposal of property and equipment 18       18 0  
In process research and development acquired from NanoTx Therapeutics         0 781  
Non-cash lease expenses         36 2  
Change in fair value of warrants (2)   81   (4) (2,342)  
Stock-based compensation expense         425 149  
Increases (decreases) in cash caused by changes in operating assets and liabilities:              
Accounts receivable         0 1,169  
Other current assets         12 516  
Other assets         0 54  
Accounts payable and accrued expenses         418 (1,586)  
Net cash used in operating activities         (7,656) (5,210)  
Cash flows used in investing activities:              
Purchases of property and equipment         (134) (37)  
Proceeds from sale of property and equipment         50 0  
In process research and development acquired from NanoTx Therapeutics         0 (400)  
Net cash used in investing activities         (84) (437)  
Cash flows provided by (used in) financing activities:              
Principal payments of long-term obligations         0 (5,307)  
Payment of financing lease liability     (42)   (8) (93)  
Proceeds from exercise of warrants         2,017 1,081  
Proceeds from sale of common stock, net         18,665 0  
Net cash provided by (used in) financing activities         20,674 (4,319)  
Net increase (decrease) in cash and cash equivalents         12,934 (9,966)  
Cash and cash equivalents at beginning of period   $ 8,346   $ 17,592 8,346 17,592 $ 17,592
Cash and cash equivalents at end of period $ 21,280   $ 7,626   21,280 7,626 $ 8,346
Cash paid during period for:              
Interest         292 470  
Supplemental schedule of non-cash investing and financing activities:              
Unpaid offering cost         139 12  
Right-of-use asset obtained in exchange for lease liabilities         81 0  
Issuance costs paid in common stock         0 463  
Common stock issued in payment for in process research and development         $ 0 $ 381